UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Clinical pharmacology and therapeutics, 2013-06, Vol.93 (6), p.502-514

2013

Volltextzugriff (PDF)

POS1025 TOFACITINIB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND PROBABLE DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.782-782

2021

Volltextzugriff (PDF)

Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Clinical pharmacology and therapeutics, 2013-06, Vol.93 (6), p.502-514

2013

Volltextzugriff (PDF)

POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.565-566

2021

Volltextzugriff (PDF)

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2010-02, Vol.69 (2), p.413-416

2010

Volltextzugriff (PDF)

SAT0165 Tofacitinib versus Biologic Treatments in Moderate To Severe Rheumatoid Arthritis Patients Who Have Had An Inadequate Response To Nonbiologic Dmards: Systematic Literature Review and Network Meta-Analysis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.726-726

2016

Volltextzugriff (PDF)

AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1042-1043

2016

Volltextzugriff (PDF)

Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis

Journal of medical economics, 2016-02, Vol.19 (2), p.101-112

2016

Volltextzugriff (PDF)

SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.969

2018

Volltextzugriff (PDF)

SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.990

2018

Volltextzugriff (PDF)

SAT0226 Early Experience with Tofacitinib: Treatment Patterns in Two us Healthcare Claims Databases

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.740-740

2015

Volltextzugriff (PDF)

AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1325

2018

Volltextzugriff (PDF)

THU0101 Real-World Evaluation of TNF Inhibitor Utilisation in Patients with Rheumatoid Arthritis in a us Claims Database

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.229-229

2015

Volltextzugriff (PDF)

THU0343 Modelling the Costs and Outcomes Associated with Sequence of Treatment with and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the US

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.319-320

2015

Volltextzugriff (PDF)

THU0132 Comparative Effectiveness of TNFI and Tofacitinib Monotherapy in Clinical Practice: Results from Corrona Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.228

2016

Volltextzugriff (PDF)

AB0275 One-Year Treatment Patterns and Healthcare Resource Use Among Patients with Rheumatoid Arthritis Newly Initiating Treatment with Biologic Dmards

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.984-984

2015

Volltextzugriff (PDF)

SAT0220 Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.737-737

2015

Volltextzugriff (PDF)

Modelling The Costs and Outcomes Associated With Sequence Of Treatment With And Without Tofacitinib For The Treatment of Moderate to Severe Rheumatoid Arthritis In The Us

Value in health, 2015-05, Vol.18 (3), p.A161-A161

2015

Volltextzugriff (PDF)

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

The New England journal of medicine, 2014-06, Vol.370 (25), p.2377-2386

2014

Volltextzugriff (PDF)

OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.118-119

2014

Volltextzugriff (PDF)

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

The New England journal of medicine, 2012-08, Vol.367 (6), p.508-519

2012

Volltextzugriff (PDF)

THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.207-207

2013

Volltextzugriff (PDF)

FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.375-375

2013

Volltextzugriff (PDF)

THU0152 How should the primary endpoint be analysed in rheumatoid arthritis trials which mandate rescue prior to the clinical endpoint? Analysis of three phase 3 trials of tofacitinib

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.207-207

2013

Volltextzugriff (PDF)

OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A65-A65

2013

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(139)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(112)
Deutsch
(33)
Französisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(35)
Humans
(32)
Male
(23)
Female
(22)
Middle Aged
(21)
Rheumatoid Arthritis
(21)
Treatment Outcome
(17)
Adult
(16)
Arthritis, Rheumatoid - Drug Therapy
(16)
Patients
(16)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Medicin Och Hälsovetenskap
(13)
Rheumatology
(12)
Double-Blind Method
(10)
Pain
(10)
Pyrimidines - Administration & Dosage
(10)
Pyrroles - Administration & Dosage
(10)
Antirheumatic Agents - Administration & Dosage
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

POS1025 TOFACITINIB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND PROBABLE DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS

Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

SAT0165 Tofacitinib versus Biologic Treatments in Moderate To Severe Rheumatoid Arthritis Patients Who Have Had An Inadequate Response To Nonbiologic Dmards: Systematic Literature Review and Network Meta-Analysis

AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database

Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis

SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months

SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial

SAT0226 Early Experience with Tofacitinib: Treatment Patterns in Two us Healthcare Claims Databases

AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference

THU0101 Real-World Evaluation of TNF Inhibitor Utilisation in Patients with Rheumatoid Arthritis in a us Claims Database

THU0343 Modelling the Costs and Outcomes Associated with Sequence of Treatment with and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the US

THU0132 Comparative Effectiveness of TNFI and Tofacitinib Monotherapy in Clinical Practice: Results from Corrona Registry

AB0275 One-Year Treatment Patterns and Healthcare Resource Use Among Patients with Rheumatoid Arthritis Newly Initiating Treatment with Biologic Dmards

SAT0220 Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib

Modelling The Costs and Outcomes Associated With Sequence Of Treatment With And Without Tofacitinib For The Treatment of Moderate to Severe Rheumatoid Arthritis In The Us

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis

FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis

THU0152 How should the primary endpoint be analysed in rheumatoid arthritis trials which mandate rescue prior to the clinical endpoint? Analysis of three phase 3 trials of tofacitinib

OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial

Suchergebnisse filtern